Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 4/20 | 0.40 |
| ▸ | ESR1 | P03372 | 9/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | SHBG | P04278 | 1/20 | 0.32 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6403812 | 0.88 | FDPS (0.40) | FDPSESR1ESR2BLMPTPN1 | |
| SCHEMBL6401068 | 0.87 | GGPS1 (0.40) | FDPSBLMGGPS1 | |
| SCHEMBL6402174 | 0.85 | ESR1 (0.37) | FDPSESR1ESR2BLMPTPN1 | |
| SCHEMBL6395047 | 0.82 | IGF1R (0.37) | FDPSESR1ESR2PTPN1SHBG | |
| SCHEMBL6401086 | 0.78 | INPPL1 (0.39) | FDPSESR1ESR2BLMPTPN1 | |
| SCHEMBL6402566 | 0.78 | ESR1 (0.35) | FDPSESR1ESR2BLMPTPN1 | |
| SCHEMBL6401196 | 0.77 | ESR1 (0.38) | ESR1ESR2 | |
| SCHEMBL6397933 | 0.76 | FDPS (0.38) | FDPSESR1ESR2BLMPTPN1 | |
| SCHEMBL6398625 | 0.76 | DRD2 (0.41) | — | |
| SCHEMBL6401094 | 0.75 | INPPL1 (0.38) | FDPSESR1ESR2BLMPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050187195-A1 | Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans | PEERCE BRIAN E (US) | 2005-08-25 | — | — | US | disclosed |
| US-20030162753-A1 | Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187195-A1 | Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans | SLC34A3, SLC34A1, SLC34A2 | FDPS 813/4885ESR1 2885/4885ESR2 2416/4885 |
| US-20030162753-A1 | Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans | SLC34A3, SLC34A1, SLC34A2 | FDPS 813/4885ESR1 2885/4885ESR2 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.